NCET2 Panel Says Angel Investors Often Reluctant to Span Spinout Funding Gap | GenomeWeb
WASHINGTON, DC — University technology-transfer offices seeking investors to help move early-stage life-science inventions to market often bemoan the fact that venture capitalists and biomedical companies are becoming increasingly hesitant to invest in such technologies.
As a result, academic tech-transfer offices and entrepreneurs are often forced to turn to individual angel investors to fill the oft-cited funding gap that develops between seed funding from friends and family and later-stage VC investments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.